HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

490.383

-13.015-2.59%

Number of Gainers:6

Number of Losers:23

Number of Flat:4

PE:- -

High:505.901

Open:503.516

Low:489.571

Close:503.398

Volume:82.72M

Turnover:2.69B

Market Cap:313.43B

Float Cap:277.25B

Loading ...

Ascletis Pharma Slips on Expecting Deeper H1 Loss on R&D Expenses

HBM Holdings to Join Hang Seng Composite Index

MT Newswires Live

PEIJIA-B Surges Over 8% in Morning Trade as Half-Year Results Signal Multiple Positive Catalysts

Press Release: Antengene Announces 2026 Interim Results: Achieves First

Shenyang Cracks Down on Illegal Veterinary Drug Sales: Two Stores Under Investigation

Sinopharm Interim Revenue Edges Down on Softness in Pharmaceutical Distribution Business

Dunhuang's Medical Heritage Blends into Tourism, Boosting Wellness Travel Along the Silk Road

mRNA Vaccine Breakthrough: From Prevention to Treatment, a Historic Leap in Oncology

ZYLOXTB Completes Share Buyback Worth Approximately HK$72,200

Zylox-Tonbridge Files HKEX Next-Day Disclosure Return on Share Repurchase for Treasury Shares

Weak Dollar and Shifting Tech Narratives: Strategists Favor Resources and Pharma

Citi Raises Keymed Bio Target Price to HK$97.5, Keeps Buy/High Risk Call

Daiwa Raises KEYMED BIO-B Price Target to HK$110, Reaffirming Buy Call

BioDlink International (SEHK:1875) Stock Rebound Meets Shrinking Revenue And Fresh Losses

Simply Wall St.

Peijia Medical (SEHK:9996) Stock Nears Breakeven As Revenue Momentum Builds

Simply Wall St.

Antengene (SEHK:6996) Stock Drops As Profit Arrives And Valuation Looms

Simply Wall St.

Keymed Biosciences Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Simply Wall St.

Niki BioSolutions Weighs Financing Options as Going-Concern Warning Clouds Post-Merger Outlook

Zai Lab CFO Chen Yajing Sells 260 ADS Worth $7,020

Ascletis Pharma Expects HY Loss of Rmb319.7 MLN

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/BK1574/news?page=13"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":490.383,"timestamp":1788250091886,"preClose":503.39795,"halted":0,"volume":82724645,"delay":0,"changeRate":-0.025854,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-13.014954,"latestTime":"09-01 16:00:00","open":503.51608,"high":505.9005,"low":489.5706,"amount":2688849767,"amplitude":0.032439,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788312600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1788226200000,1788235200000],[1788238800000,1788249600000]],"pbRate":3.790203,"peRate":127.340212,"turnoverRate":0.003099,"increases":6,"decrements":23,"flats":3,"marketCap":313429262448,"floatMarketCap":277247178824},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":505.9005,"amplitude":0.032439,"preClose":503.39795,"low":489.5706,"pbRate":"3.790203","latestPrice":490.383,"volume":82724645,"delay":0,"open":503.51608,"prevYearClose":556.26263,"prevWeekClose":523.873,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":512.773,"twentyDayClose":475.248,"sixtyDayClose":459.637,"secType":"PLATE","market":"HK","turnoverRate":0.003099,"peRate":127.340212,"marketCap":313429262448,"floatMarketCap":277247178824,"timestamp":1788250091886,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":23,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:13,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661240309","title":"Ascletis Pharma Slips on Expecting Deeper H1 Loss on R&D Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2661240309","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661240309?lang=en_us&edition=fundamental","pubTime":"2026-08-24 11:43","pubTimestamp":1787542991,"startTime":"0","endTime":"0","summary":"BUZZ-Ascletis Pharma slips on expecting deeper H1 loss on R&D expenses** Shares of Ascletis Pharma Inc1672.HKslip 4.5% to HK$9.565, on track for the biggest one-day pct drop since August 10** The viral diseases and oncology focused pharmaceutical products developerexpects to record net lossof 319.7 million yuan  six months ended in June, as compared with a loss of 88 million yuan the same period a year ago** Company said deeper loss is due to significant increase in research and development expenses as it advances its comprehensive metabolic disease pipeline, including both small molecules and peptides** YTD, stock down 15.9%, while Hang Seng Biotech Index.HSBIOup 9.9%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL1N44L03A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01672","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661247019","title":"HBM Holdings to Join Hang Seng Composite Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2661247019","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661247019?lang=en_us&edition=fundamental","pubTime":"2026-08-24 11:28","pubTimestamp":1787542115,"startTime":"0","endTime":"0","summary":"HBM Holdings (HKG:2142) will be added to the Hang Seng Composite Index from Sept. 7, according to a Monday Hong Kong bourse filing.Its shares are also expected to meet the criteria to be traded through the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DRAL","MUYY","YANG","KWEB","YINN","XPP","DRAM","DRMY","82822","02823","82823","ASHS","DISK","KBA","RAM","02822","DRMP","HSCI","YXI","CHAU","KCAI","HBMX","RAMZ","MUD","82843","MUG","MUU","02843","BK1583","BK1574","FLCH","MUZ","BK4588","BK1161","ASHR","FXP","MIC","MULL","02142","CWEB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171609154","title":"PEIJIA-B Surges Over 8% in Morning Trade as Half-Year Results Signal Multiple Positive Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=1171609154","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171609154?lang=en_us&edition=fundamental","pubTime":"2026-08-24 10:48","pubTimestamp":1787539696,"startTime":"0","endTime":"0","summary":"Shares of PEIJIA-B (09996) showed strong momentum during the morning session on August 24, climbing more than 8%. The company recently released its interim results, which highlighted robust key...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159891","09996","BK1583","BK1100","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661410992","title":"Press Release: Antengene Announces 2026 Interim Results: Achieves First","url":"https://stock-news.laohu8.com/highlight/detail?id=2661410992","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661410992?lang=en_us&edition=fundamental","pubTime":"2026-08-24 09:00","pubTimestamp":1787533200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Aug. 23, 2026 /PRNewswire/ -- Antengene Corporation Limited (\"Antengene\", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065731478.USD","COAL","R","HCC","LU0963586101.USD","06996","BK4588","IE00B19Z4B17.USD","TM","BK1191","03160","BK4022","CRS","IE00B66KJ199.SGD","BK4585","PYZ","BK4187","CR","BK4232","ORR","BK4604","BK4161","BK4555","BK4099","XAR","IE00B7SZL793.SGD","BK1583","IE0031619046.USD","BK1574","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109288534","title":"Shenyang Cracks Down on Illegal Veterinary Drug Sales: Two Stores Under Investigation","url":"https://stock-news.laohu8.com/highlight/detail?id=1109288534","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109288534?lang=en_us&edition=fundamental","pubTime":"2026-08-24 08:50","pubTimestamp":1787532633,"startTime":"0","endTime":"0","summary":"On August 24, the Agriculture and Rural Affairs Bureau of Yuhong District, Shenyang, issued a public notice regarding a media report from the previous day about veterinary drug stores in the Zhangshi...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661241804","title":"Sinopharm Interim Revenue Edges Down on Softness in Pharmaceutical Distribution Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2661241804","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661241804?lang=en_us&edition=fundamental","pubTime":"2026-08-24 08:02","pubTimestamp":1787529767,"startTime":"0","endTime":"0","summary":"Sinopharm interim revenue edges down on softness in pharmaceutical distribution businessOverviewChina pharmaceutical distributor's interim revenue declined slightly year-on-yearNet income attributable","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL1N44K04V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4204","BK1587","LU0640798160.USD","BK1161","HK0000320264.USD","BK1230","01099","BK1500","02696","HK0000306685.HKD","HK0000320223.HKD","BK1515","HK0000306701.USD","BK1197","LU1115378108.SGD","HK0000165453.HKD","EDMCQ","BK1574","00656","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135663784","title":"Dunhuang's Medical Heritage Blends into Tourism, Boosting Wellness Travel Along the Silk Road","url":"https://stock-news.laohu8.com/highlight/detail?id=1135663784","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135663784?lang=en_us&edition=fundamental","pubTime":"2026-08-23 20:51","pubTimestamp":1787489466,"startTime":"0","endTime":"0","summary":"This summer, the rich tapestry of Dunhuang's medical culture—from the \"moxibustion charts\" painted on its ancient grotto walls to the \"prescription collections\" and the legendary \"immortal porridge\"...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","09939","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119759096","title":"mRNA Vaccine Breakthrough: From Prevention to Treatment, a Historic Leap in Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=1119759096","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119759096?lang=en_us&edition=fundamental","pubTime":"2026-08-23 19:20","pubTimestamp":1787484034,"startTime":"0","endTime":"0","summary":"On August 19, 2026, the pharmaceutical world was set ablaze. US drug giants Moderna and Merck jointly announced the successful Phase III INTerpath-001 clinical trial of their personalized mRNA...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","159938","09939","BK1515","MRNX","BK1574","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134790180","title":"ZYLOXTB Completes Share Buyback Worth Approximately HK$72,200","url":"https://stock-news.laohu8.com/highlight/detail?id=1134790180","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134790180?lang=en_us&edition=fundamental","pubTime":"2026-08-23 18:32","pubTimestamp":1787481162,"startTime":"0","endTime":"0","summary":"On August 21, 2026, ZYLOXTB (02190) announced that it had repurchased 3,500 shares at a cost of approximately HK$72,200. The buyback was executed at a price range of HK$20.6 to HK$20.62 per share.The...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1587","02190","BK1100","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661824851","title":"Zylox-Tonbridge Files HKEX Next-Day Disclosure Return on Share Repurchase for Treasury Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2661824851","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661824851?lang=en_us&edition=fundamental","pubTime":"2026-08-23 18:20","pubTimestamp":1787480425,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge files HKEX next-day disclosure return on share repurchase for treasury sharesZylox-Tonbridge filed a next-day disclosure return showing 3,500 H shares repurchased on Aug. 21 for treasu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260823:nNDL5xQ3Yr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1587","02190","BK1583","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119594086","title":"Weak Dollar and Shifting Tech Narratives: Strategists Favor Resources and Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=1119594086","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119594086?lang=en_us&edition=fundamental","pubTime":"2026-08-23 16:42","pubTimestamp":1787474551,"startTime":"0","endTime":"0","summary":"Founder Securities has released a research report indicating that the market showed a pattern of initial gains followed by losses this week. After a rapid rebound in the early period, major indices...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","TTTN","BK4588","02834","BK1147","09086","159938","UUP","BK1515","VGT","UDN","09939","07266","07261","07568","BK4585","DBND","XLK","BK1161","03086","03034","09834","03455","07522"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143799433","title":"Citi Raises Keymed Bio Target Price to HK$97.5, Keeps Buy/High Risk Call","url":"https://stock-news.laohu8.com/highlight/detail?id=1143799433","media":"Deep News","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143799433?lang=en_us&edition=fundamental","pubTime":"2026-08-23 12:50","pubTimestamp":1787460624,"startTime":"0","endTime":"0","summary":"Citi has released a research report stating that KEYMED BIO-B (02162) posted first-half 2026 revenue of RMB 617 million, up 24% year-on-year. Within that total, sales of stapokibart reached RMB 393...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125154935.USD","LU0128525689.USD","LU0130517989.USD","EWH","BK1587","LU0203347892.USD","LU1267930227.SGD","LU2462157665.USD","C","BK4588","LU1074936037.SGD","LU1506573853.SGD","LU2360032135.SGD","LU1366192091.USD","BK1574","IE00BSNM7G36.USD","TFNS","BK4504","LU0477156953.USD","IYF","LU1244550577.SGD","LU0170899867.USD","LU1791807156.HKD","LU2125154778.USD","BK1161","LU0130102774.USD","BK4559","LU0314106906.USD","LU0320765646.SGD","BK4207","LU1668664300.SGD","LU2417539215.USD","BK4534","LU1201861249.SGD","BK4585","FTXO","LU0648001328.SGD","LU1244550494.USD","LU2236285917.USD","LU0052756011.USD","BK4566","LU0980610538.SGD","LU0203345920.USD","LU0106831901.USD","LU0072461881.USD","BK1583","LU0098860793.USD","LU1244550221.USD","LU2456880835.USD","LU0310800965.SGD","LU1144417596.USD","LU0162691827.USD","LU1162221912.USD","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174192289","title":"Daiwa Raises KEYMED BIO-B Price Target to HK$110, Reaffirming Buy Call","url":"https://stock-news.laohu8.com/highlight/detail?id=1174192289","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174192289?lang=en_us&edition=fundamental","pubTime":"2026-08-23 12:40","pubTimestamp":1787460029,"startTime":"0","endTime":"0","summary":"Daiwa has released a research report stating that KEYMED BIO-B (02162) 2026 first-half results broadly aligned with its previous profit alert and the firm's estimates. Management has raised the 2026...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","EWH","BK1587","BK1574","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661121751","title":"BioDlink International (SEHK:1875) Stock Rebound Meets Shrinking Revenue And Fresh Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2661121751","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661121751?lang=en_us&edition=fundamental","pubTime":"2026-08-23 08:30","pubTimestamp":1787445032,"startTime":"0","endTime":"0","summary":"BioDlink International has been trading like a recovery story, with the stock up about 17% over the past month. However, H1 2026 results underline that this is still a loss making biotech with a valuation built on hope rather than profit. The headline this half is the profit squeeze. Revenue came in at ¥246.011 million, while net income excluding extra items showed a loss of ¥58.517 million and basic earnings per share were also in the red. The share price reaction now rests on how long...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1875/biodlink-international-shares/news/biodlink-international-sehk1875-stock-rebound-meets-shrinkin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1875/biodlink-international-shares/news/biodlink-international-sehk1875-stock-rebound-meets-shrinkin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK1161","GXDW","VGFPF","DECU","VOTE","PMDE","RGLO","JOYT","FEBU","01875"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661217313","title":"Peijia Medical (SEHK:9996) Stock Nears Breakeven As Revenue Momentum Builds","url":"https://stock-news.laohu8.com/highlight/detail?id=2661217313","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661217313?lang=en_us&edition=fundamental","pubTime":"2026-08-23 07:18","pubTimestamp":1787440688,"startTime":"0","endTime":"0","summary":"Peijia Medical stock closed at HK$4.98 on the day of its H1 2026 release after a choppy few months that left the 90 day return in decline. The market came in focused on whether the company could keep shrinking losses while still pushing top line growth in high end cardiovascular devices.\nThe headline is that Peijia Medical is selling more while bleeding far less. Revenue for H1 2026 reached ¥424.5m, while the net loss narrowed sharply to ¥7.6m. For long term investors in this still...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/healthcare/hkg-9996/peijia-medical-shares/news/peijia-medical-sehk9996-stock-nears-breakeven-as-revenue-mom","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-9996/peijia-medical-shares/news/peijia-medical-sehk9996-stock-nears-breakeven-as-revenue-mom","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1100","09996","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661212911","title":"Antengene (SEHK:6996) Stock Drops As Profit Arrives And Valuation Looms","url":"https://stock-news.laohu8.com/highlight/detail?id=2661212911","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661212911?lang=en_us&edition=fundamental","pubTime":"2026-08-23 04:28","pubTimestamp":1787430511,"startTime":"0","endTime":"0","summary":"The market has spent the past week marking Antengene lower, with the stock down about 10% over seven days, yet the latest numbers tell a very different story. H1 2026 landed with a sharp swing into profit, with basic earnings per share at ¥0.34 and net income of ¥216.345 million on revenue of ¥513.076 million. For a high P/E stock trading at about 42.4x trailing earnings, this move into the black is the headline. The key question now is whether this profitability burst can justify that...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6996/antengene-shares/news/antengene-sehk6996-stock-drops-as-profit-arrives-and-valuati","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6996/antengene-shares/news/antengene-sehk6996-stock-drops-as-profit-arrives-and-valuati","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VOTE","JOYT","RGLO","BK1191","FEBU","PMDE","BK1583","VGFPF","DECU","BK1574","06996","GXDW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661215890","title":"Keymed Biosciences Inc. Just Missed Earnings - But Analysts Have Updated Their Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2661215890","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661215890?lang=en_us&edition=fundamental","pubTime":"2026-08-22 07:01","pubTimestamp":1787353294,"startTime":"0","endTime":"0","summary":"Investors in Keymed Biosciences Inc. ( HKG:2162 ) had a good week, as its shares rose 2.8% to close at HK$80.30...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-inc-just-missed-earnings-but-analysts-hav","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-inc-just-missed-earnings-but-analysts-hav","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["FEBU","BK1583","BK1574","VOTE","GXDW","RGLO","BK1161","BK1587","JOYT","VGFPF","DECU","02162","PMDE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661901362","title":"Niki BioSolutions Weighs Financing Options as Going-Concern Warning Clouds Post-Merger Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2661901362","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661901362?lang=en_us&edition=fundamental","pubTime":"2026-08-22 05:15","pubTimestamp":1787346928,"startTime":"0","endTime":"0","summary":"Niki BioSolutionsweighs financing options as going-concern warning clouds post-merger outlookOverviewUS biopharmaceutical developer's H1 net loss widened, with loss per share at $1.6Operating expenses","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nL1N44I0TG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YS42.EUR","BK1515","BK1589","01177","BK1583","BK1191","BK1521","HK0000165453.HKD","IE00BZ08YT58.USD","BK1587","BK4139","06996","IE00BZ08YR35.GBP","BK1574","NIKI","BK1161","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661297920","title":"Zai Lab CFO Chen Yajing Sells 260 ADS Worth $7,020","url":"https://stock-news.laohu8.com/highlight/detail?id=2661297920","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661297920?lang=en_us&edition=fundamental","pubTime":"2026-08-22 04:17","pubTimestamp":1787343447,"startTime":"0","endTime":"0","summary":"Zai Lab CFO Chen Yajing sells 260 ADS worth $7,020Zai Lab CFO Chen Yajing sold 260 American Depositary Shares on Aug. 19, 2026 at USD 27.Post-transaction holdings totaled 35,635 ADS, held directly.Tra","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDLN7hqj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Zai Lab CFO Chen Yajing Sells 260 ADS Worth $7,020","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","BK1588","BK1574","BK1161","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661291392","title":"Ascletis Pharma Expects HY Loss of Rmb319.7 MLN","url":"https://stock-news.laohu8.com/highlight/detail?id=2661291392","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661291392?lang=en_us&edition=fundamental","pubTime":"2026-08-21 23:45","pubTimestamp":1787327122,"startTime":"0","endTime":"0","summary":"BRIEF-Ascletis Pharma Expects HY Loss Of RMB319.7 MLNAug 21 (Reuters)-Ascletis Pharma Inc1672.HK:EXPECTS LOSS OF RMB319.7 MILLION FOR H1 2026, UP 263.5% YOYEXPECTED HY RESULT AS RESEARCH AND DEVELOPMENT EXPENSES INCREASED 132.7% TO RMB341.7 MILLION, OTHERSFurther company coverage:1672.HK","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1515","01672"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":20,"pageCount":13,"totalSize":381,"code":"91000000","status":"200"}]}}